Sara Mato, Lorenzo Carità, Ariadna Colmenero, Mara Andrés, Olga Balagué, Maitane Andión, Itziar Astigarraga, Verónica Celis, Carmen Mendoza, Pilar Guerra-García, Lorena Valero, Ana Galera, María Tallón, Melina Pol, Natalia Castrejón-de-Anta, Leonie Frauenfeld, Noelia Garcia, Elías Campo, Itziar Salaverria, Jaime Verdú-Amorós
{"title":"儿童和青少年复发难治性成熟b细胞非霍奇金淋巴瘤的综合分析。","authors":"Sara Mato, Lorenzo Carità, Ariadna Colmenero, Mara Andrés, Olga Balagué, Maitane Andión, Itziar Astigarraga, Verónica Celis, Carmen Mendoza, Pilar Guerra-García, Lorena Valero, Ana Galera, María Tallón, Melina Pol, Natalia Castrejón-de-Anta, Leonie Frauenfeld, Noelia Garcia, Elías Campo, Itziar Salaverria, Jaime Verdú-Amorós","doi":"10.1111/bjh.20012","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of <i>TP53</i> as a biomarker in R/R B-NHL. <i>TP53</i> mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; <i>p</i> = 0.048).</p>\n </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"206 5","pages":"1390-1396"},"PeriodicalIF":3.8000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents\",\"authors\":\"Sara Mato, Lorenzo Carità, Ariadna Colmenero, Mara Andrés, Olga Balagué, Maitane Andión, Itziar Astigarraga, Verónica Celis, Carmen Mendoza, Pilar Guerra-García, Lorena Valero, Ana Galera, María Tallón, Melina Pol, Natalia Castrejón-de-Anta, Leonie Frauenfeld, Noelia Garcia, Elías Campo, Itziar Salaverria, Jaime Verdú-Amorós\",\"doi\":\"10.1111/bjh.20012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of <i>TP53</i> as a biomarker in R/R B-NHL. <i>TP53</i> mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; <i>p</i> = 0.048).</p>\\n </div>\",\"PeriodicalId\":135,\"journal\":{\"name\":\"British Journal of Haematology\",\"volume\":\"206 5\",\"pages\":\"1390-1396\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2025-02-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/bjh.20012\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/bjh.20012","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents
The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of TP53 as a biomarker in R/R B-NHL. TP53 mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; p = 0.048).
期刊介绍：
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
